April Rose

Assistant Professor

McGill University

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Cancer Biology Cancer Biology professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

April Rose is an Assistant Professor at McGill University in Canada. Her research focuses on cancer progression and treatment, particularly in relation to HER2+ and BRAF-mutant cancers, as reflected in her recent publications. She explores clinical outcomes, precision therapies, and metabolic profiles associated with various cancer types, aiming to improve therapeutic strategies and patient outcomes.

Articles (13)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (8)

Marcus Butler

University Health Network

CANADA

View details

Kelsie Thu

Assistant Professor

University of Toronto

CANADA

View details

Gaia Griguolo

University of Padua

ITALY

View details

Andrea Quaiattini

McGill University

CANADA

View details

Matthew Dankner

McGill University

CANADA

View details

George Zogopoulos

McGill University

CANADA

View details

David W. Cescon

University Health Network

CANADA

View details

Sai Sakktee Krisna

Teaching Assistant

McGill University Faculty of Medicine

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

April Rose

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre

The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers

Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to Immunotherapy

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Non-small-cell lung cancer: how to manage BRAF-mutated disease

Gender Disparities in Academic Outcomes Among Graduates of a Canadian MD-PhD Program

Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer

The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER <sup>+</sup> breast cancer with mitotic aberrations

Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors

Pegylated Liposomal Doxorubicin and Kidney-Limited Thrombotic Microangiopathy in a Kidney Transplant Recipient: A Case Report

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy

HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin

Collaborators (8)

Marcus Butler

Kelsie Thu

Gaia Griguolo

Andrea Quaiattini

Matthew Dankner

George Zogopoulos

David W. Cescon

Sai Sakktee Krisna

Make your next move.